Safety and Tolerability of IDO-1 Inhibition in the Prevention of EBV-related Pathology in EBV Negative Kidney Transplant Recipients Receiving an Organ From EBV Positive Donors

NCT07368153 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

9

Enrollment

OTHER

Sponsor class

Conditions

EBV Infections
Kidney Transplant

Interventions

DRUG: indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor
DRUG: placebo

Sponsor

University Hospital, Basel, Switzerland

Collaborators

[object Object]